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Abstract: Eating disorders are severe illnesses characterized by both psychiatric and metabolic factors.
We explored the prospective role of metabolic risk in eating disorders in a UK cohort (n = 2929
participants), measuring 158 metabolic traits in non-fasting EDTA-plasma by nuclear magnetic
resonance. We associated metabolic markers at 7 years (exposure) with risk for anorexia nervosa
and binge-eating disorder (outcomes) at 14, 16, and 18 years using logistic regression adjusted
for maternal education, child’s sex, age, body mass index, and calorie intake at 7 years. Elevated
very low-density lipoproteins, triglycerides, apolipoprotein-B/A, and monounsaturated fatty acids
ratio were associated with lower odds of anorexia nervosa at age 18, while elevated high-density
lipoproteins, docosahexaenoic acid and polyunsaturated fatty acids ratio, and fatty acid unsaturation
were associated with higher risk for anorexia nervosa at 18 years. Elevated linoleic acid and n-6
fatty acid ratios were associated with lower odds of binge-eating disorder at 16 years, while elevated
saturated fatty acid ratio was associated with higher odds of binge-eating disorder. Most associations
had large confidence intervals and showed, for anorexia nervosa, different directions across time
points. Overall, our results show some evidence for a role of metabolic factors in eating disorders
development in adolescence.
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1. Introduction
Eating disorders commonly emerge in adolescence or young adulthood and can have a relapsing
course with severe long-term consequences including comorbid psychiatric disorders, such as
depression and obsessive-compulsive disorder, as well as increased mortality and suicide [1,2].
All eating disorders are characterized by disordered eating behaviors, ranging from extreme restriction,
commonly seen in anorexia nervosa, to uncontrolled binge eating reported by patients with binge-eating
disorder, alongside cognitive symptoms such as extreme focus on and dissatisfaction with weight
and shape [3]. Eating disorders have complex etiologies, influenced by genetic, behavioral, and
environmental factors [4]. Therefore, the application of metabolomics in eating disorders may help
disentangle the contributions of these components. The metabolome is the furthest downstream
product of genome–environment interactions, potentially rendering it a direct and sensitive measure
of eating disorders phenotypes at the molecular level. Large-scale genome-wide association studies
(GWAS) of anorexia nervosa have interrogated the metabolic component of this illness [5,6]. Results
indicated a positive genetic correlation between genetic variants associated with anorexia nervosa
and high-density lipoprotein cholesterol, as well as negative genetic correlations with fasting insulin
and fasting glucose [7]. The role of insulin in anorexia nervosa has been described previously [7,8].
A systematic review [7] highlighted that anorexia nervosa is associated with increased insulin sensitivity
whilst bulimia nervosa and binge-eating disorder are associated with decreased insulin sensitivity.
Furthermore, longitudinal research has indicated that starvation, common in anorexia nervosa, can
have long-term metabolic consequences [8]. Even though eating disorders can affect people across
the entire weight spectrum, binge-eating disorder and overweight/obesity commonly co-occur [9,10].
Indeed, previous research has highlighted that binge-eating disorder is associated with a high burden
of metabolic risk factors and particularly higher fasting glucose (the latter independently of body mass
index (BMI)) [10].
It is often assumed that metabolic differences are consequences of eating disorders; however,
previous research has highlighted that eating disorders are preceded by differential BMI trajectories as
well as persistent eating perturbations, such as childhood fussy eating, overeating, and fasting [11–13].
These findings suggest the possibility that individuals at risk for eating disorders show differential
metabolic profiles prior to diagnosis. However, it is unknown if differences in metabolic markers
precede the onset of eating disorders. In this exploratory study, we assessed for the first time the
prospective associations between blood metabolic markers at 7 years and anorexia nervosa and
binge-eating disorder in adolescence, using data from the Avon Longitudinal Study of Parents and
Children (ALSPAC), a large UK birth cohort. Logistic regression was used to examine the associations
of each EDTA-plasma metabolic traits at 7 years old with either of anorexia nervosa and binge-eating
disorder assessed at 14, 16, 18, and cumulatively by 18 years.
2. Results
We investigated the association between 158 metabolic traits at 7 years with anorexia nervosa
(Figures 1 and 2) and binge-eating disorder (Figures 3 and 4) at 14 (blue), 16 (red), 18 years (green), and
cumulatively until 18 years (black). For our main analyses, we fitted 1264 logistic regression models
that indicate whether an elevated metabolic trait level is associated with lower or higher risk of an
eating disorder diagnosis in adolescence. We present the data by plotting the point estimates (circles or
dots) and respective confidence intervals (error bars) in forest plots (Figures 1–4) where metabolic traits
are clustered by biochemical classes defined by core chemical structure (e.g., fatty acids) or metabolic
pathway (e.g., glycolysis). In forest plots, the points to right of the vertical black line that marks the
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baseline risk (i.e., 1) indicate elevated risk for an eating disorder whereas points on the left of the black
vertical line indicate lower risk for an eating disorder in adolescence.Metabolites 2019, 9, 191 6 of 17 
 
 
Figure 1. Estimated odds ratios for anorexia nervosa at 14, 16, 18 years of age and cumulatively across 
all three time points according to lipid-related metabolic trait concentrations at 7 years. Estimates refer 
to 1 standard deviation increase in metabolic trait concentration at 7 years (see also Table S2, 
Supplementary File). Error bars = 95% confidence intervals (CI). For lipoprotein subclasses, the total 
lipids (= triglycerides + phospholipids + total cholesterol) point estimate (and CIs) of each 14 
subclasses is presented. Estimated odds ratios and corresponding 95% CIs for particle concentration 
and specific lipids in each lipoprotein subclass are given in Figure S1a–c, Supplementary Material and 
Table S2, Supplementary File. Abbreviations: AN = anorexia nervosa; C = cholesterol; IDL = 
intermediate-density lipoprotein; LDL = low-density lipoprotein; HDL = high-density lipoprotein; 
VLDL = very low-density lipoprotein. Note: Filled dot: CI do not include the null. 
Figure 1. Estimated odds ratios for anorexia nervosa at 14, 16, 18 years of age and cumulatively across
all three time points according to lipid-related metabolic trait concentrations at 7 years. Estimates
refer to 1 standard deviation increase in metabolic trait concentration at 7 years (see also Table S2,
Supplementary File). Error bars = 95% confidence intervals (CI). For lipoprotein subclasses, the total
lipids (= triglycerides + phospholipids + total cholesterol) point estimate (and CIs) of each 14 subclasses
is presented. Estimated odds ratios and corresponding 95% CIs for particle concentration and specific
lipids in each lipoprotein subclass are given in Figure S1a–c, Supplementary Material and Table S2,
Supplementary File. Abbreviations: AN = anorexia nervosa; C = cholesterol; IDL = intermediate-density
lipoprotein; LDL = low-density lipoprotein; HDL = high-density lipoprotein; VLDL = very low-density
lipoprotein. Note: Filled dot: CI do not include the null.
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Figure 2. Estimated odds ratios for anorexia nervosa at 14, 16, 18 years of age and cumulatively across 
all three time points according to lipid- and non-lipid-related metabolic trait concentrations at 7 years 
(Figure 1 continued). Estimates refer to 1 standard deviation increase in metabolic trait concentration 
at 7 years. Error bars = 95% confidence intervals (CI). Abbreviations: AN = anorexia nervosa; MUFA 
= monounsaturated fatty acids; PUFA = polyunsaturated fatty acids. Note: Filled dot: CI do not 
include the null. MUFA, PUFA and saturated fatty acid concentrations include all fatty acids detected 
which have one, more than one, or zero C=C double bonds in their backbone, respectively. 
i 2. Estimated odds ratios for anorexia nervosa at 14, 16, 18 years of age and cumulatively
cross all three time points acc rding to lipid- and non-lipid-related metab li trait c centration
at 7 y ars (Figur 1 continued). Estimates refe to 1 standard deviation increase in metabolic rait
concentration at 7 years. Err r bars = 95% confidence inter als (CI). bbreviations: AN = anorexia
nervosa; MUFA = monounsaturated fatty acids; PUFA = polyunsaturated fa ty acids. N e: Filled d :
CI do not include the null. MUFA, PUFA n s ur te fatty acid concentrations include all fatty acids
detected which have one, m r than one, or zero C=C double bonds in their backbone, respectively.
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Figure 3. Estimated odds ratios for binge-eating disorder at 14, 16, 18 years of age and cumulatively 
across all three time points according to lipid-related metabolic trait concentrations at 7 years. 
Estimates refer to 1 standard deviation increase in metabolic trait concentration at 7 years (see also 
Table S3, Supplementary File). Error bars = 95% confidence intervals (CI). For lipoprotein subclasses, 
the total lipids (= triglycerides + phospholipids + total cholesterol) point estimate (and CIs) of each 14 
subclasses is presented. Estimated odds ratios and corresponding 95% CIs for particle concentration 
and specific lipids in each lipoprotein subclass are given in Figure S6a–c, Supplementary Material and 
Table S3, Supplementary File. Abbreviations: BED = binge-eating disorder; C = cholesterol; IDL = 
intermediate-density lipoprotein; LDL = low-density lipoprotein; HDL = high-density lipoprotein; 
VLDL = very low-density lipoprotein. Note: Filled dot: CI do not include the null. 
Figure 3. Estimated odds ratios for binge-eating disorder at 14, 16, 18 years of age and cumulatively
across all three time points according to lipid-related metabolic trait concentrations at 7 years. Estimates
refer to 1 standard deviation increase in metabolic trait concentration at 7 years (see also Table S3,
Supplementary File). Error bars = 95% confidence intervals (CI). For lipoprotein subclasses, the
total lipids (= triglycerides + phospholipids + total cholesterol) point estimate (and CIs) of each 14
subclasses is presented. Estimated odds ratios and corresponding 95% CIs for particle concentration
and specific lipids in each lipoprotein subclass are given in Figure S6a–c, Supplementary Material
and Table S3, Supplementary File. Abbreviations: BED = binge-eating disorder; C = cholesterol;
IDL = intermediate-density lipoprotein; LDL = low-density lipoprotein; HDL = high-density lipoprotein;
VLDL = very low-density lipoprotein. Note: Filled dot: CI do not include the null.
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Figure 4. Estimated odds ratios for binge-eating disorder at 14, 16, 18 years of age and cumulatively 
across all three time points according to lipid- and non-lipid-related metabolic trait concentrations at 
7 years (Figure 3 continued). Estimates refer to 1 standard deviation increase in metabolic trait 
concentration at 7 years. Error bars = 95% confidence intervals (CI). Abbreviations: BED = binge-eating 
disorder; MUFA = monounsaturated fatty acids; PUFA = polyunsaturated fatty acids. Note: Filled dot: 
CI do not include the null. MUFA, PUFA and saturated fatty acid concentrations include all fatty 
acids detected which have one, more than one, or zero C=C double bonds in their backbone, 
respectively. 
3. Discussion 
To the best of our knowledge, this is the first study to explore the prospective role of metabolic 
risk factors in the development of eating disorders. In this population-based study of adolescents 
who experienced anorexia nervosa or binge-eating disorder at ages of 14, 16, 18 or lifetime up to 18 
years, we detected alterations in lipid traits at age 7 years that were associated with higher or lower 
odds of anorexia nervosa at 18 years or binge-eating disorder at age 16 years. We did not detect 
alterations in glycolysis-related metabolic traits or amino acid concentrations at age 7 that were 
prospectively associated with an eating disorder diagnosis. 
In contrast to our study, previous research on blood markers and eating disorders has primarily 
focused on anorexia nervosa and explored the hypothesis that metabolic changes are a consequence 
of eating disorders by comparing individuals with current anorexia nervosa with individuals after 
t i ti i r r t , ,
ll t ree ti e points a cording to lipid- and non-lipid-related metabolic trait concentrations
at 7 years (Figure 3 continued). Estimates r fer to 1 standard deviation increase i li
95 co fi : i -
Fille dot:
not include the null. MUFA, PUFA and saturated fatty acid oncentrations include all fatty acids
detected which have one, more than ne, or zero C=C double bonds in their backbone, respectively.
2.1. Descriptives
Table 1 shows the distributions of participant characteristics at 7 years (age at metabolic profiling)
included in this study (n = 2929) and stratified by eating disorder diagnosis at age 14, 16, 18 years old
and cumulatively across all available time points (from 14 until 18 years). We only included those
ALSPAC participants who had available metabolomic and phenotype data.
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Table 1. Participant characteristics (n = 2929) at 7 years old stratified by eating disorders diagnosis at
age 14, 16, 18 years old and cumulatively across all available time points (i.e., eating disorder diagnosis
at age 14, 16, or 18 years old) in the Avon Longitudinal Study of Parents and Children (ALSPAC). Eating
disorders diagnoses were derived using questionnaire data and DSM-5 criteria. Note: * indicates
p-value < 0.006.
Eating Disorders
Status by
Assessment Age
n (%) Female[n (%)]
Age (years)
[mean (SD)]
Body Mass Index
(kg/m2)
[mean (SD)]
Average Total
Calorie Intake
(kcal)
[mean (SD)]
Mother >12 Years
in Education
[n (%)]
Anorexia Nervosa (N = 2907)
Diagnosis at 14 Years Old
No Eating
Disorder 2224 (96) 1057 (48)* 7.5 (0.1) 15.9 (1.8)* 1726.3 (304.7)* 1113 (50)
Anorexia Nervosa 87 (4) 61 (70)* 7.5 (0.1) 14.6 (1.3)* 1639.4 (255.8)* 40 (46)
Diagnosis at 16 Years Old
No Eating
Disorder 1615 (97) 729 (45)* 7.5 (0.1) 15.7 (1.6)* 1729.4 (305.0)* 853 (53)
Anorexia Nervosa 48 (3) 37 (77)* 7.4 (0.1) 14.5 (0.9)* 1565.8 (261.0)* 25 (52)
Diagosis at 18 Years Old
No Eating
Disorder 1498 (98) 697 (47)* 7.4 (0.1) 15.8 (1.7)* 1728.9 (304.1) 814 (54)
Anorexia Nervosa 26 (2) 21 (81)* 7.5 (0.1) 14.6 (1.4)* 1673.7 (248.9) 15 (58)
Cumulatively Across All Available Time Points (i.e., Eating Disorder Diagnosis at Age 14, 16, or 18 Years Old)
No Eating
Disorder 1146 (90) 655 (57) 7.4 (0.1) 16.1 (1.8)* 1725.9 (301.6)* 650 (57)
Anorexia Nervosa 127 (10) 88 (69) 7.5 (0.1) 14.6 (1.2)* 1636.8 (267.5)* 63 (50)
Binge-Eating Disorder (N = 2879)
Diagnosis at 14 Years Old
No Eating
Disorder 2240 (99) 1070 (48) 7.5 (0.1) 15.9 (1.8) 1723.3 (304.6) 1122 (50)
Binge-Eating
Disorder 14 (1) 8 (57) 7.4 (0.1) 16.4 (1.1) 1714.6 (422.2) 4 (29)
Diagnosis at 16 Years Old
No Eating
Disorder 1620 (99) 732 (45)* 7.5 (0.1) 15.7 (1.6)* 1729.7 (304.5) 857 (53)
Binge-Eating
Disorder 21 (1) 17 (81)* 7.4 (0.2) 16.7 (1.4)* 1854.9 (263.8) 10 (48)
Diagnosis at 18 Years Old
No Eating
Disorder 1498 (98) 697 (47)* 7.4 (0.1) 15.8 (1.7) 1728.9 (304.1) 814 (54)
Binge-Eating
Disorder 25 (2) 20 (80)* 7.4 (0.1) 16.8 (1.9) 1744.1 (329.6) 15 (60)
Cumulatively Across All Available Time Points (i.e., Eating Disorder Diagnosis at Age 14, 16, or 18 Years Old)
No Eating
Disorder 1146 (97) 655 (57) 7.4 (0.1) 16.1 (1.8) 1725.9 (301.6) 650 (57)
Binge-Eating
Disorder 36 (3) 27 (75) 7.4 (0.1) 16.6 (1.7) 1808.7 (267.8) 21 (58)
In our subsample, 4%, 3%, 2%, and 10% of participants met diagnositic criteria for anorexia
nervosa at 14, 16, 18 years, and cumulatively at all three time points, respectively (Table 1). Binge-eating
disorder was diagnosed in 1%, 1%, and 2% at 14, 16, and 18 years, respectively, and in 3% of participants
by age 18 years (Table 1). Adolescents who experienced anorexia nervosa or binge-eating disorder at
any of the time points were primarily female.
On average, adolescents who experienced anorexia nervosa at any of the time points had lower
BMI and lower total calorie intake at age 7 compared with individuals who did not experience an eating
disorder in adolescence (all p-value < 0.006). Only average calorie intake at 7 years for participants who
experienced anorexia nervosa at 18 years was comparable with controls (p-value = 0.23). At age 7 years
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and on average, participants who later developed binge-eating disorder had comparable BMIs and
total calorie intake to individuals free from eating disorders at any later time point. Only participants
with binge-eating disorder at age 16 had higher BMIs than the reference group at age 7 years (p-value
= 0.005). Maternal education was comparable between participants diagnosed with either anorexia
nervosa or binge-eating disorder and participants without any eating disorders.
In addition, Table S1 (Supplementary Materials) presents characteristics for the following: all
offspring in ALSPAC (n = 19,290), offspring that attended 7 years clinic (n = 8293) and offspring
included in this study (n = 2929). Participants with information on any of the exposures of interest
(n = 2929) had higher educated mothers when compared to all offspring in ALSPAC (50% vs. 23% with
mothers with more than 12 years in education, respectively).
2.2. Metabolic Markers Associated with Anorexia Nervosa
First, we present that lipid markers elevated at age 7 years were associated with lower risk for
anorexia nervosa at age 18 years, indicated by an odds ratio (OR) below 1. Higher concentrations
of very low-density lipoprotein (VLDL) (all subclasses except very small VLDL), very low-density
lipoprotein particle size (OR = 0.5, 95% CI = 0.3 to 0.9), total triglycerides (OR = 0.4, 95% CI = 0.3 to 1),
very low-density lipoprotein triglycerides (for example, extremely large, OR = 0.4, 95% CI = 0.2 to 0.9),
and monounsaturated fatty acid ratio (OR = 0.6, 95% CI = 0.4 to 0.9) at 7 years were associated with
lower odds for anorexia nervosa at age 18 years (green filled points in Figures 1 and 2 and Table S2,
Supplementary Materials).
Second, the following lipid markers at age 7 years were associated with higher risk for anorexia
nervosa at age 18 years, indicated by an OR above 1: Elevated high-density lipoprotein particle size
(OR = 1.6, 95% CI = 1.1 to 2.3), cholesterol in high-density lipoprotein (for example, total cholesterol in
large high-density lipoprotein, OR = 1.6, 95% CI = 1.1 to 2.4), fatty acid unsaturation (OR = 1.6, 95% CI
= 1.1 to 2.4), docosahexaenoic acid ratio (OR = 1.4, 95% CI = 1.1 to 1.9) and polyunsaturated fatty acid
ratio (OR = 1.7, 95% CI = 1 to 2.6) at age 7 years were associated with higher odds for anorexia nervosa
at age 18 years (green filled points in Figures 1 and 2, Figure S1a–c and Table S2, Supplementary
Materials).
Higher apolipoprotein B/A-I at 7 years old was associated with lower odds of anorexia nervosa
at 14 (OR = 0.8, 95% CI = 0.6 to 1, blue point Figure 1) and 18 years (OR = 0.6, 95% CI = 0.4 to 1,
green point Figure 1). No glycolysis-related trait nor amino acids measured at age 7 years showed an
association in our exploratory study.
2.3. Metabolic Markers Associated with Binge-Eating Disorder
First, we present the lipid markers that when elevated at age 7 years were associated with lower
risk for binge-eating disorder at age 16 years, indicated by an odds ratio (OR) below 1: Free cholesterol
(OR = 0.6, 95% CI = 0.4 to 0.97), total cholesterol (OR = 0.6, 95% CI = 0.4 to 1.0), linoleic acid (OR = 0.6,
95% CI = 0.3 to 0.9), polyunsaturated fatty acid ratio (OR = 0.7, 95% CI = 0.5 to 0.97), and acetate
(OR = 0.5, 95% CI = 0.3 to 1.0) were associated with lower odds of binge-eating disorder at 16 years
(red filled points in Figures 3 and 4, Figure S6a–c and Table S3, Supplementary Materials). In addition,
linoleic acid ratio and n-6 fatty acid ratio were also associated with lower risk for binge-eating disorder
at 16 years and with binge-eating disorder cumulatively by 18 years.
Second, the following lipid markers at age 7 years were associated with higher risk for binge-eating
disorder at age 16 years, indicated by an OR above 1: Higher saturated fatty acid ratio at 7 years was
associated with increased odds of binge-eating disorder at 16 years (OR = 1.6, 95% CI = 1.0 to 2.5).
We observed no association between glycolysis-related metabolic traits and amino acids at age 7 years
and binge-eating disorder in adolescence.
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2.4. Sensitivity Analyses
We also conducted a sensitivity analysis (see Section 4.4.) to explore how much of the association
was confounded by BMI or calorie intake. Findings were broadly comparable across models with
similar point estimates and overlapping CI (for example, for the association between anorexia nervosa
and total fatty acids at 18 years, all point estimates were approximately OR = 0.8, 95% CI = 0.5 to
1.2). For anorexia nervosa, associations for creatinine attenuated by BMI adjustment across the four
time points. Forest plots comparing across models with different adjustments can be found in Figures
S2a–S5b, 7a–10b, Supplementary Materials.
3. Discussion
To the best of our knowledge, this is the first study to explore the prospective role of metabolic
risk factors in the development of eating disorders. In this population-based study of adolescents who
experienced anorexia nervosa or binge-eating disorder at ages of 14, 16, 18 or lifetime up to 18 years,
we detected alterations in lipid traits at age 7 years that were associated with higher or lower odds of
anorexia nervosa at 18 years or binge-eating disorder at age 16 years. We did not detect alterations
in glycolysis-related metabolic traits or amino acid concentrations at age 7 that were prospectively
associated with an eating disorder diagnosis.
In contrast to our study, previous research on blood markers and eating disorders has primarily
focused on anorexia nervosa and explored the hypothesis that metabolic changes are a consequence of
eating disorders by comparing individuals with current anorexia nervosa with individuals after weight
recovery and/or healthy controls. These approaches did not address whether metabolic alterations are
detectable in individuals who go on to develop an eating disorder later in life.
In addition, only one study [8] has used a metabolomics platform (Biocrates Life Sciences, mass
spectroscopy, 163 metabolites, 29 women, 16 years old) to quantify metabolic traits. The remainder
used standard biochemistry assays. The problem with biochemistry assays is that they only measure
an extremely limited number of metabolic traits in human specimens, such as blood, cerebrospinal
fluid, sputum, or feces. To overcome this limitation, we measured detailed blood metabolic traits
(n = 158 traits). Commonly, metabolomics platforms quantify hundreds of metabolic traits from a
biological sample (two orders of magnitude more than clinical chemistry assays) providing a broader
molecular signature from multiple metabolic pathways potentially affected by eating disorders and
therefore offer greater coverage than standard biochemistry assays.
Due to the limited number of previous studies and differences in methods, direct comparison
between our study and previous literature is difficult as we explored the hypothesis that metabolic
abnormalities are ‘traits’ of eating disorders and therefore precede their onset and may be classified as
risk factors.
In our analysis, the following lipid traits were associated with lower odds for anorexia nervosa at
age 18 years: We observed lower odds of anorexia nervosa at age 18 years with elevated very low-density
lipoprotein at age 7 years independent from BMI. Very low-density lipoproteins transport endogenous
produced lipids from the liver to peripheral tissues. A meta-analysis observed no association between
very low-density lipoprotein and anorexia nervosa in acutely ill patients [14]. However, only three
studies with 90 anorexia nervosa cases were included to obtain the pooled estimate and heterogeneity
was high. Additionally, measurements in weight-recovered anorexia nervosa patients were missing.
A recent GWAS reported a positive genetic correlation between anorexia nervosa and high-density
lipoprotein cholesterol [5], meaning that patients with anorexia nervosa carry genetic variants that
predispose them to elevated high-density lipoprotein cholesterol concentrations. High-density
lipoproteins transport cholesterol from peripheral tissues to the liver. Our results were in line with
this observation, we found higher odds of anorexia nervosa at 18 years with higher concentration of
high-density lipoproteins at age 7 years.
Furthermore, we observed an association between elevated very low-density lipoprotein
triglycerides at age 7 years with lower risk for anorexia nervosa in adolescence. No differences
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in very low-density lipoprotein triglycerides have been reported in an observational study comparing
acutely ill anorexia nervosa patients with healthy controls [15]. Additionally, a higher concentration of
triglycerides [14] has been observed in anorexia nervosa patients; however, they tend to normalize
after weight restoration [5]. In contrast, we found that higher concentrations of triglycerides at 7 years
were associated with lower risk of anorexia nervosa at 18 years.
Hypercholesterolemia is a common finding in acutely ill anorexia nervosa patients with higher levels
of total cholesterol. However, total cholesterol of anorexia nervosa patients returns to concentrations
within the normative range after weight recovery [5]. We did not observe a prospective association of
total cholesterol with anorexia nervosa in adolescence, suggesting that hypercholesterolemia may be a
state rather than a trait in anorexia nervosa.
Moreover, both GWAS [5,6] reported a negative genetic correlation between anorexia nervosa and
fasting glucose, suggesting that patients with anorexia nervosa carry genetic variants that predispose
them to lower fasting glucose concentrations. We, however, found no associations between anorexia
nervosa case status in adolescence and glucose or glycolysis-related metabolic traits in childhood.
However, this finding must be interpreted extremely cautiously as non-fasting blood samples were
taken at age 7.
Currently, the literature regarding biochemistry in binge-eating disorder is very limited and no
GWAS of binge-eating disorder has yet been performed that would allow the interpretation of potential
shared genetics between metabolic traits and binge-eating disorder. However, our study has generated
new hypotheses regarding the potential implication of certain metabolic traits in the development of
binge-eating disorder. We observed an association between higher cholesterol and higher linoleic acid
at age 7 years and lower risk for binge-eating disorder at age 16 years. Linoleic acid is an essential
fatty acid that must be obtained through diet. We, therefore, hypothesize that children who develop
binge-eating disorder later in life may show altered eating behavior as early as age 7 years. In fact,
previous research in the sample has suggested that children who were reported to persistently overeat
during the first ten years of life were at higher risk of engaging in binge eating in adolescence [12].
Previous genetic, retrospective case-control, and prospective research showed that a high BMI is
associated with higher risk of binge-eating disorder [16–20] and metabolic and weight abnormalities
seen in binge-eating disorder are for the most part opposite to those seen in anorexia nervosa [21].
Nonetheless, in our study, individuals who experienced binge-eating disorder in adolescence had, on
average, comparable BMIs to their peers at age 7 years; except those who experienced binge-eating
disorder at age 16 who had higher BMIs than the reference group at age 7 years (p-value = 0.005).
Participants who experienced anorexia nervosa in adolescence had, on average, lower BMIs at 7 years
old than the reference group.
Overall, we did not observe differences in direction of associations between metabolic traits and
binge-eating disorder across time points (Figure S11a–d, Supplementary Materials). It is, however,
unclear, why we observed differences for most metabolic traits in the directions of associations with
anorexia nervosa across time points. It is possible that at each time point the anorexia nervosa
group reflects different etiologies of eating disorders with early onset cases capturing more severe
cases. Alternatively, it could be an artifact of the very small sample size and small number of cases.
Additionally, anorexia nervosa diagnosis at 18 years did not include parental report, unlike previous
time points. This heterogeneity in direction of associations across the three time points may explain
why point estimates for anorexia nervosa in the cumulative analysis, across time points until 18 years
old, were mostly null.
In models without BMI adjustment, higher creatinine at 7 years was associated with a lower
odds of anorexia nervosa in adolescence. After adjusting for BMI, associations attenuated towards the
null, suggesting that body size drove the association between creatinine and anorexia nervosa as total
muscle mass, which is captured by BMI, is the most important determinant of the creatine pool size
and therefore of creatine production.
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Limitations should be considered when evaluating the results of our study. First, blood samples
were drawn from non-fasting participants. If individuals who experience eating disorders in adolescence
exhibited eating disorder behaviors as early as age 7, then blood fasting status could confound
associations for fasting-labile metabolic traits. However, most blood metabolic traits seem to be
unaffected by fasting status [22–26]. Even so, glucose and extremely large very low-density lipoprotein
traits (as defined by this NMR platform, see Appendix A) may be affected as the latter have possible
contributions of chylomicrons which are particles, only produced after meals, that transport dietary
lipids from the intestines to other locations in the body. Nonetheless, we anticipate that most of
this potential confounding would be captured by BMI and calorie intake measured at 7 years that
we included in sensitivity analysis due to their association with eating behaviors. However, our
results must be seen in the light of this limitation and future studies and data collection must sample
participants after an appropriate fasting period.
Second, we cannot exclude the possibility of selection bias due to loss-to-follow-up. We found that
participants included in this study had more educated mothers compared to all offspring-participants
included in ALSPAC.
Third, due to the small number of individuals who experienced eating disorders and resulting
uncertainty of our effect estimates (particularly for binge-eating disorder), these findings need to be
replicated in larger cohorts. However, currently no other cohort that assessed metabolic profiles and
eating disorder pathology prospectively is available. Hence, this is an exploratory study, and the first
to assess the prospective role of metabolic risk factors in eating disorders development in which we
focused on general patterns of associations.
Fourth, currently no single or combination of metabolomics technologies can characterize the
entire metabolome [27]. Nonetheless, the metabolic traits measured represent a broad molecular
signature of systemic metabolism and many of which are related to multiple pathways affected in
eating disorders, such as lipids, glycolysis-related metabolites, and amino acids, which exceeds any
previous study of biomarkers in eating disorders.
In conclusion, we have shown evidence of some association between metabolic factors in childhood
and development of eating disorders in adolescence. We observed differences in very low-density
lipoprotein, high-density lipoprotein, and fatty acid traits in anorexia nervosa, and total and free
cholesterol and fatty acid traits in binge-eating disorder. Our findings encourage replication and
extension in larger well-characterized cohorts as such data become available.
4. Materials and Methods
4.1. Study Population
We studied offspring participating in the ALSPAC, a prospective pregnancy/birth cohort that was
established to explore how genetic and environmental characteristics influence health and development
in parents and children [28,29]. During 1990-92, recruitment enrolled pregnant women resident in the
former region of Avon, South West of England, with an expected date of delivery between 1st April
1991 and 31st December 1992. Offspring who were alive at 1 year (n = 13,988) have since been followed
at regular intervals [29], with an additional 713 children enrolled over the course of the study.
Ethical approval for the study was obtained from the ALSPAC Ethics and Law
Committee and the Local Research Ethics Committee and all ethical codes can be found
on http://www.bristol.ac.uk/medialibrary/sites/alspac/documents/governance/Research%20Ethics%
20Committee%20approval%20references.pdf. Ethical codes for 7 year old clinic are United Bristol
Healthcare Trust: E4168 ALSPAC Hands on Assessments at Age Seven (30th September 1998);
Southmead Health Services: 67/98 Avon Longitudinal Study of Pregnancy and Childhood (ALSPAC)
Hands on Assessments at Age Seven (14th September 1998); Frenchay Healthcare Trust: 98/52 Avon
Longitudinal Study of Pregnancy and Childhood (ALSPAC); Hands on Assessments at Age Seven (8th
December 1998). Consent for biological samples has been collected in accordance with the Human
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Tissue Act (2004). Informed consent for the use of data collected via questionnaires and clinics was
obtained from participants following the recommendations of the ALSPAC Ethics and Law Committee
at the time. The main caregiver initially provided consent for child participation and from the age
16 years the offspring themselves have provided informed written consent. Details of all data are
available through a fully searchable data dictionary at www.bristol.ac.uk/alspac/researchers/our-data.
The current study included 127 and 36 offspring who had experienced anorexia nervosa or
binge-eating disorder, respectively, by age 18 and up to 2240 controls from whom a blood metabolome
profile at 7 years of age was available.
4.2. Eating Disorders Diagnoses and Covariates
Anorexia nervosa and binge-eating disorder diagnoses, at 14, 16, and 18 years, according to DSM-5
criteria, were obtained as described previously [20]. Anorexia nervosa or binge-eating disorder by
age 18 was defined as all individuals who were diagnosed with anorexia nervosa or binge-eating
disorder at any one of the three time points: 14, 16, or 18 years, and had not crossed over to another
eating disorder. The reference group was individuals who had not experienced any eating disorder,
nor eating disorders symptoms by age 18 years, as well as participants who had not experienced
any eating disorder, nor eating disorders symptoms, at 14 and 16 years, but had missing data at 18
years. Maternal education was obtained by questionnaire during pregnancy and used as an indicator
of family socioeconomic position (A levels or higher, lower than A levels; A levels are needed to
enroll in university in the UK). The participants’ sex was obtained from obstetric records and age was
calculated from their dates of birth and dates of questionnaires or clinic assessments at age 7 years.
BMI was calculated from measurements collected during clinical assessments when participants were
approximately 7 years old. Height was measured in light clothing without shoes to the nearest 0.1 cm
using a Harpenden stadiometer and weight was recorded to the nearest 0.1 kg using a Tanita scale.
BMI was calculated as weight (kg) divided by the square of height (m2). Calorie intake at 7 years was
assessed through a food frequency questionnaire as extensively described previously [30].
4.3. EDTA-Plasma Metabolome Profiling
A high-throughput (1H) NMR metabolomics platform, Nightingale Health© (Helsinki, Finland),
was used to quantify 158 metabolic traits in children’s non-fasting EDTA-plasma collected at 7 years
old. The platform quantifies routine lipids, 14 lipoprotein subclasses, including particle concentration
and lipids transported by these particles (see Appendix A), various fatty acids and fatty acids traits
(e.g., chain length, degree of unsaturation, see Appendix A), amino acids, ketone bodies, glycolysis
and gluconeogenesis-related metabolites, fluid balance, and one inflammation-related metabolite.
This set of metabolic traits represent a broad molecular signature of systemic metabolism [31] and
most are quantified in clinically meaningful concentrations (e.g., mmol/L). Fatty acids were modelled
in original units and as ratios (expressed in %) to total fatty acids. Details of this platform and its
use in epidemiological studies have been described elsewhere [32–36]. In addition, we calculated the
phenylalanine/tyrosine ratio as it was shown to be a marker of catabolism in individuals with anorexia
nervosa [37,38].
4.4. Statistical Analysis
All metabolic traits were standardized by subtracting the sample mean and dividing by the
sample standard deviation (SD), as this allows comparison across metabolic traits with different
units and/or different concentration ranges. Logistic regression was used to examine the associations
of each EDTA-plasma metabolic traits at 7 years old with either anorexia nervosa or binge-eating
disorder assessed at 14, 16, 18, and cumulatively by 18 years. Associations are reported as odds ratios
(OR) reflecting the change in odds of anorexia nervosa or binge-eating disorder per 1 SD increase in
metabolic trait concentration at 7 years old. We fitted four models: in model 1, ORs were adjusted
for maternal education and child’s sex and age; model 2, had the same covariates as model 1 plus
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child’s BMI at 7 years; model 3, was as model 1 plus child’s calorie intake at 7 years; and model 4 as
model 1 with further adjustment for child’s BMI and calorie intake at 7 years. These confounders
were decided a priori, we report the results of model 4 in our main analyses and comparison across
models is shown in Supplementary Material. Our study is exploratory and we focus on effect size and
precision [39,40]. All analyses were conducted using Stata version 14.1 (Stata Inc., TX, USA) and R
version 3.5.1 (R Foundation for Statistical Computing, Vienna, Austria).
Supplementary Materials: The following are available online at http://www.mdpi.com/2218-1989/9/9/191/s1,
Figure S1a–c: Estimated odds ratios for anorexia nervosa (AN) at 14, 16, 18 years of age and cumulatively across
all three time points according to lipoprotein subclasses particle and lipid concentrations at 7 years; Figure S2a,b:
Estimated odds ratios for anorexia nervosa (AN) at 14 years of age according to metabolic trait concentrations at 7
years; Figure S3a,b: Estimated odds ratios for anorexia nervosa (AN) at 16 years of age according to metabolic
trait concentrations at 7 years; Figure S4a,b: Estimated odds ratios for anorexia nervosa (AN) at 18 years of age
according to metabolic trait concentrations at 7 years; Figure S5a,b: Estimated odds ratios for anorexia nervosa
(AN) by 18 years of age (i.e., cumulatively across 14, 16, 18 years old) according to metabolic trait concentrations
at 7 years; Figure S6a–c: Estimated odds ratios for binge-eating disorder (BED) at 14, 16, 18 years of age and
cumulatively across all three time points according to lipoprotein subclasses particle and lipid concentrations
at 7 years; Figure S7a,b: Estimated odds ratios for binge-eating disorder (BED) at 14 years of age according to
metabolic trait concentrations at 7 years; Figure S8a,b: Estimated odds ratios for binge-eating disorder (BED) at
16 years of age according to metabolic trait concentrations at 7 years, Figure S9a,b: Estimated odds ratios for
binge-eating disorder (BED) at 18 years of age according to metabolic trait concentrations at 7 years, Figure S10a, b:
Estimated odds ratios for binge-eating disorder (BED) by 18 years of age (i.e., cumulatively across 14, 16, 18 years
old) according to metabolic trait concentrations at 7 years, Figure S11a–d: Estimated odds ratios for binge-eating
disorder (BED) and anorexia nervosa (AN) at 14, 16, 18 years of age and cumulatively across all three time points
according to metabolic trait concentration at 7 years; Table S1: Distribution of background characteristics according
to follow-up information available in the Avon Longitudinal Study of Parents and Children (ALSPAC) cohort;
Supplementary File: Table S2: Estimated odds ratios for anorexia nervosa (AN) at 14, 16, 18 years of age and
cumulatively across all three time points according to metabolic trait concentrations at 7 years. Estimates refer
to 1 standard deviation increase in metabolic trait concentration at 7 years; Table S3: Estimated odds ratios for
binge-eating disorder (BED) at 14, 16, 18 years of age and cumulatively across all three time points according
to metabolic trait concentrations at 7 years. Estimates refer to 1 standard deviation increase in metabolic trait
concentration at 7 years.
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Appendix A
Lipoprotein Subclasses and Fatty Acids Details
Each lipoprotein measurement is characterized by three elements: size (e.g., extremely large,
very large, large, medium, small, very small), density (e.g., very low-density lipoprotein (VLDL),
intermediate-density lipoprotein (IDL), low-density lipoprotein (LDL), high-density lipoprotein (HDL))
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and trait (e.g., particle concentration, total lipids, triglycerides, phospholipids, total cholesterol,
cholesterol esters, free cholesterol). The definition of the 14 lipoprotein subclass are as follows: six
subclasses of VLDL: extremely large VLDL (particle diameters from 75 nm upwards and possible
chylomicrons contributions), alongside 5 other VLDL subclasses (average particle diameters of 64.0 nm,
53.6 nm, 44.5 nm, 36.8 nm, and 31.3 nm); IDL (28.6 nm), 3 LDL subclasses (25.5 nm, 23.0 nm, and 18.7 nm),
and 4 HDL subclasses (14.3 nm, 12.1 nm, 10.9 nm, and 8.7 nm) [7]. The lipoproteins traits obtained
are the concentration of the lipoprotein size–density–trait combination in the total serum sample.
For example, 0.5 mmol/l of very large VLDL cholesterol means 0.5 mmol of cholesterol embedded
in very large VLDL particles per liter of serum or EDTA-plasma. Remnant cholesterol was defined
as VLDL-cholesterol + IDL-cholesterol, which is equivalent to total-cholesterol −HDL-cholesterol −
LDL-cholesterol [41]. For fatty acids (FA), only the cis configuration was quantified since the trans
fatty acids are below the platform’s detection limit [41].
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